Brought to you by 
Argos Therapeutics brings in $25mm through its Series D venture round
30 Aug 2013
Executive Summary
Argos Therapeutics Inc. (immunotherapeutics) has raised $25mm through its Series D venture round. Forbion Capital led and was joined by other current shareholders TVM Capital, Lumira Capital, Intersouth Partners, Caisse de depot et placement du Quebec, Morningside Group, and Aurora Funds. Proceeds will be used to start an international Phase III study of fast-tracked AGS003 in metastatic renal cell carcinoma by mid-year.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Argos Therapeutics brings in $25mm through its Series D venture round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice